Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of JNJ-73763989 ± JNJ-56136379 with nucleos(t)ide analog and pegylated interferon alfa-2a in treatment-naive HBeAg-positive chronic hepatitis B
jRCT2080225335Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, open-label trial of tomligisiran in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080225335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225335.